Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefapixant - Merck & Co

Drug Profile

Gefapixant - Merck & Co

Alternative Names: AF-219; MK-7264; R1646; RG-1646; RO 4926219

Latest Information Update: 30 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Merck & Co; Roche
  • Class Analgesics; Antiasthmatics; Antitussives; Pyrimidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cough
  • Phase II Asthma; Interstitial cystitis; Musculoskeletal pain; Pain; Pelvic pain
  • Phase I Sleep apnoea syndrome
  • Discontinued Overactive bladder

Most Recent Events

  • 14 Jul 2020 Merck Sharp & Dohme completes a phase II trial for Pelvic pain (PO) in USA, New Zealand, Ukraine, Russia, Puerto Rico, Poland, Chile, Australia and Spain (NCT03654326)
  • 15 May 2020 Pharmacokinetics data from a clinical study in Cough presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
  • 15 May 2020 Efficacy data from a phase IIb trial in Cough presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top